Axa
ACOR

Axa’s Acorda Therapeutics ACOR Stock Holding History

Axa’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-805
Closed -$277K – 1351
2019
Q3 		$277K Sell
805
-1,201
-60% -$653K ﹤0.01% 1199
2019
Q2 		$1.85M Buy
2,006
+1,805
+898% +$2.22M 0.01% 861
2019
Q1 		$320K Sell
201
-24
-11% -$43.2K ﹤0.01% 1181
2018
Q4 		$421K Buy
+225
New +$490K ﹤0.01% 1123
2018
Q3 		– Sell
-70
Closed -$241K – 1406
2018
Q2 		$241K Buy
+70
New +$214K ﹤0.01% 1276
2015
Q4 		– Sell
-263
Closed -$835K – 1515
2015
Q3 		$835K Sell
263
-321
-55% -$1.24M ﹤0.01% 946
2015
Q2 		$2.34M Sell
584
-241
-29% -$931K 0.01% 763
2015
Q1 		$3.29M Sell
825
-111
-12% -$508K 0.01% 692
2014
Q4 		$4.59M Buy
936
+572
+157% +$2.45M 0.02% 577
2014
Q3 		$1.48M Buy
364
+19
+6% +$71.3K 0.01% 826
2014
Q2 		$1.4M Sell
345
-14
-4% -$57.1K 0.01% 857
2014
Q1 		$1.63M Buy
359
+19
+6% +$76.8K 0.01% 817
2013
Q4 		$1.19M Buy
340
+17
+5% +$66.3K 0.01% 882
2013
Q3 		$1.33M Buy
323
+65
+25% +$280K 0.01% 814
2013
Q2 		$1.02M Buy
+258
New +$1.06M 0.01% 834

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Axa's ACOR Position: Q4 2019 in Review

Axa sold out of Acorda Therapeutics (ACOR) in Q4 2019, closing a stake of 805 shares — an estimated $277K sold.

Axa first reported a position in ACOR in Q2 2013 and held it in 15 quarters. The position peaked at $4.59M in Q4 2014. 121 funds tracked by Wall St. Rank hold ACOR as of Q4 2019.

  • Axa reported no remaining Acorda Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Axa sold 805 Acorda Therapeutics shares in Q4 2019, an estimated $277K.
  • Axa first reported a position in Acorda Therapeutics in Q2 2013 and held it in 15 quarters.
  • Axa's Acorda Therapeutics position peaked at $4.59M in Q4 2014.
  • 121 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2019.

Based on Axa's 13F filing for Q4 2019, filed 18 Feb 2020.